Ann: Becoming a substantial holder RM, page-9

Yes it is Cash.

When Mini was doing one of the roadshows after the (milestone) AACR results disclosure she mentioned about being surprised with this 'spontaneous secondary remission' result. Baker mentioned it again yesterday and the fact that ALA-101 can cross the blood brain barrier. He suggested other neurological (brain) indications may also be worth investigating. It certainly has potential.

I don't see the company being set up to be sold. Baker keeps banging on about acquiring and developing assets and milestones and the like so I expect them to sold off individually once they get to a marketable stage. In one of the roadshows after AACR Baker intimated that they were 'speaking with some people' presumably that they had met at the conference. Unfortunately SUD and EMS and PNO and OBJ and ACR and BIT and every other ASX micro says the same so probably not worth hanging your hat on - although to be fair Baker (under Hoppers tutorage) has bought ALA a very long way. I expect it's more likely that ALA merges with the other Hopper companies.

The AACR data was the first major win for ALA. The success in vitro of the ALA-101 and onCARlytics JV and the progression to in vivo trials with data published this year might be the next big thing.